Smoking addiction is a serious problem in this modern era. Smoking leads to lung cancer, pancreatic cancer and other cancers. Scientists from The Scripps Research Institute (TSRI) have designed an effective nicotine vaccine. The study was published recently in the Journal of Medicinal Chemistry. “This study provides new hope that one could make a nicotine vaccine that succeeds in clinical trials,” said Kim Janda, the Ely R. Callaway Jr. Professor of Chemistry and member of the Skaggs Institute for Chemical Biology at TSRI. Nicotine vaccines train the body to see nicotine as a foreign invader. To prompt this immune response, nicotine derivatives called haptens are attached to a larger carrier protein used in other approved vaccines. The body reacts to the vaccine by creating antibodies to bind specifically to nicotine molecules. When a person later uses tobacco, the anti-nicotine antibodies stop the nicotine molecules from entering the central nervous system and ever reaching the brain. The researchers believe purifying nicotine hapten mixtures is an important and practical step in creating future nicotine vaccines.
This article is based on materials provided by: http://www.scripps.edu/news/press/2015/20150112janda.html
The original article can be accessed at: http://pubs.acs.org/doi/abs/10.1021/jm501625j
Disclaimer: This article does not reflect any personal views of the authors/editors